NASDAQ:GHDX - Genomic Health Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $56.28 +1.66 (+3.04 %) (As of 05/22/2019 06:48 AM ET)Previous Close$54.62Today's Range$53.80 - $57.435052-Week Range$36.94 - $92.18Volume596,836 shsAverage Volume476,493 shsMarket Capitalization$2.09 billionP/E Ratio53.60Dividend YieldN/ABeta0.88 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California. Receive GHDX News and Ratings via Email Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GHDX Previous Symbol CUSIP37244C10 CIK1131324 Webhttp://www.genomichealth.com/ Phone650-556-9300Debt Debt-to-Equity Ratio0.19 Current Ratio5.67 Quick Ratio5.67Price-To-Earnings Trailing P/E Ratio53.60 Forward P/E Ratio38.55 P/E GrowthN/A Sales & Book Value Annual Sales$394.11 million Price / Sales5.29 Cash Flow$1.5056 per share Price / Cash Flow37.38 Book Value$7.77 per share Price / Book7.24Profitability EPS (Most Recent Fiscal Year)$1.05 Net Income$25.68 million Net Margins10.35% Return on Equity18.70% Return on Assets14.85%Miscellaneous Employees829 Outstanding Shares37,072,000Market Cap$2.09 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Genomic Health (NASDAQ:GHDX) Frequently Asked Questions What is Genomic Health's stock symbol? Genomic Health trades on the NASDAQ under the ticker symbol "GHDX." How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) issued its quarterly earnings data on Tuesday, May, 7th. The medical research company reported $0.34 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.29 by $0.05. The medical research company had revenue of $108.80 million for the quarter, compared to the consensus estimate of $106.75 million. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The firm's revenue for the quarter was up 17.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. View Genomic Health's Earnings History. When is Genomic Health's next earnings date? Genomic Health is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Genomic Health. What price target have analysts set for GHDX? 9 Wall Street analysts have issued 12-month price targets for Genomic Health's shares. Their forecasts range from $33.00 to $86.00. On average, they expect Genomic Health's stock price to reach $62.1667 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Price Targets for Genomic Health. What is the consensus analysts' recommendation for Genomic Health? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 7 hold ratings, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health. Has Genomic Health been receiving favorable news coverage? Media coverage about GHDX stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genomic Health earned a news impact score of -1.0 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Genomic Health's key competitors? Some companies that are related to Genomic Health include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Fulgent Genetics (FLGT), PotNetwork (POTN), Psychemedics (PMD), Biocept (BIOC) and Avant Diagnostics (AVDX). What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include NVIDIA (NVDA), Revance Therapeutics (RVNC), Horizon Therapeutics (HZNP), Illumina (ILMN), Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX), Evolus (EOLS), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH) and Incyte (INCY). Who are Genomic Health's key executives? Genomic Health's management team includes the folowing people: Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)Mr. G. Bradley Cole, Chief Financial Officer (Age 63)Dr. Frederic G. Pla, Chief Operating Officer (Age 60)Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56) Who are Genomic Health's major shareholders? Genomic Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.56%), Renaissance Technologies LLC (6.42%), Acadian Asset Management LLC (2.41%), Goldman Sachs Group Inc. (2.10%), Man Group plc (1.54%) and FMR LLC (1.43%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health. Which major investors are selling Genomic Health stock? GHDX stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, AQR Capital Management LLC, Federated Investors Inc. PA, FMR LLC, Loomis Sayles & Co. L P, DE Burlo Group Inc. and BlueMountain Capital Management LLC. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kimberly J Popovits, Laura Leber and Steven Shak. View Insider Buying and Selling for Genomic Health. Which major investors are buying Genomic Health stock? GHDX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Man Group plc, Fiera Capital Corp, BlackRock Inc., Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Acadian Asset Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Genomic Health. How do I buy shares of Genomic Health? Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Genomic Health's stock price today? One share of GHDX stock can currently be purchased for approximately $56.28. How big of a company is Genomic Health? Genomic Health has a market capitalization of $2.09 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe. What is Genomic Health's official website? The official website for Genomic Health is http://www.genomichealth.com/. How can I contact Genomic Health? Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected] MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 340 (Vote Underperform)Total Votes: 627MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Return On Assets Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.